AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
Search
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
A Holistic Approach to Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Our Blueprint for Constructing a Holistic Approach to Cardio-renal-metabolic Care
AI-Driven Model Validated to Predict Risk of CKD Progression
Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.
Queen Latifah and Bernie Williams star in Boehringer Ingelheim’s “Beyond Breathless” documentary on A&E
Queen Latifah and Bernie Williams star
Welcome to the Neuroscience Gallery | Boehringer Ingelheim US
Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.
Embracing Differences: Our journey to diversity, equity, and inclusion
Embracing Differences: Our journey to diversity, equity, and inclusion
0055.06_paid_time_off_policy-bipi.pdf
Paid time off Policy BIPI
The Importance of Drug Discovery | R&D | Boehringer Ingelheim US
Research & Development
Expanded Access Programs
Expanded Access Programs
Introducing Ingelvac Provenza™ | Boehringer Ingelheim US
Find out more on our new swine vaccine, offering increased protection against influenza strains affecting 70% of growing pigs annually.
Meet our 2023 HBA Luminary award winner honored for inspiring others
Meet our 2023 HBA Luminary award winner honored for inspiring others
Life forward - Boehringer Ingelheim unveils its evolved company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Shelter Bowl: These pets looking for a new home were the big winners
Dogs and cats in a pair of shelters were met with generous donations – and some footballs - thanks to a program committed to improving their future and well-being.
BI Cares Financial Contributions Program: Strengthening Communities
BI Cares Financial Contributions Program: Strengthening Communities
FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US
FDA approves PRADAXA for the prophylaxis of DVT & PE in patients who have undergone a hip replacement. View ISI, PI and Med Guide.
Heart Diseases
Heart Diseases
Planting Trees to Help Care for the Environment
Planting Trees to Help Care for the Environment
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
A Unique Bond: human and animal health
A Unique Bond: human and animal health
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies